Copyright Reports & Markets. All rights reserved.

Global and China Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Surgery
    • 1.2.3 Targeted Therapy
    • 1.2.4 Radiation Therapy
    • 1.2.5 Chemotherapy
    • 1.2.6 Ablation
    • 1.2.7 Embolization
    • 1.2.8 Others
  • 1.3 Market by Application
    • 1.3.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospitals
    • 1.3.3 Clinics
    • 1.3.4 Ambulatory Surgical Centers
    • 1.3.5 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Perspective (2015-2026)
  • 2.2 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Growth Trends by Regions
    • 2.2.1 Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Historic Market Share by Regions (2015-2020)
    • 2.2.3 Gastrointestinal Stromal Tumors (GISTs) Treatment Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Gastrointestinal Stromal Tumors (GISTs) Treatment Players by Market Size
    • 3.1.1 Global Top Gastrointestinal Stromal Tumors (GISTs) Treatment Players by Revenue (2015-2020)
    • 3.1.2 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Players (2015-2020)
  • 3.2 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue
  • 3.4 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Concentration Ratio
    • 3.4.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue in 2019
  • 3.5 Key Players Gastrointestinal Stromal Tumors (GISTs) Treatment Area Served
  • 3.6 Key Players Gastrointestinal Stromal Tumors (GISTs) Treatment Product Solution and Service
  • 3.7 Date of Enter into Gastrointestinal Stromal Tumors (GISTs) Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Gastrointestinal Stromal Tumors (GISTs) Treatment Breakdown Data by Type (2015-2026)

  • 4.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Historic Market Size by Type (2015-2020)
  • 4.2 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Forecasted Market Size by Type (2021-2026)

5 Gastrointestinal Stromal Tumors (GISTs) Treatment Breakdown Data by Application (2015-2026)

  • 5.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Historic Market Size by Application (2015-2020)
  • 5.2 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size (2015-2026)
  • 6.2 North America Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Type (2015-2020)
  • 6.3 North America Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Application (2015-2020)
  • 6.4 North America Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size (2015-2026)
  • 7.2 Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Type (2015-2020)
  • 7.3 Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Application (2015-2020)
  • 7.4 Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size (2015-2026)
  • 8.2 China Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Type (2015-2020)
  • 8.3 China Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Application (2015-2020)
  • 8.4 China Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size (2015-2026)
  • 9.2 Japan Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Type (2015-2020)
  • 9.3 Japan Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Application (2015-2020)
  • 9.4 Japan Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size (2015-2026)
  • 10.2 Southeast Asia Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Pfizer
    • 11.1.1 Pfizer Company Details
    • 11.1.2 Pfizer Business Overview
    • 11.1.3 Pfizer Gastrointestinal Stromal Tumors (GISTs) Treatment Introduction
    • 11.1.4 Pfizer Revenue in Gastrointestinal Stromal Tumors (GISTs) Treatment Business (2015-2020))
    • 11.1.5 Pfizer Recent Development
  • 11.2 Bayer
    • 11.2.1 Bayer Company Details
    • 11.2.2 Bayer Business Overview
    • 11.2.3 Bayer Gastrointestinal Stromal Tumors (GISTs) Treatment Introduction
    • 11.2.4 Bayer Revenue in Gastrointestinal Stromal Tumors (GISTs) Treatment Business (2015-2020)
    • 11.2.5 Bayer Recent Development
  • 11.3 Novartis
    • 11.3.1 Novartis Company Details
    • 11.3.2 Novartis Business Overview
    • 11.3.3 Novartis Gastrointestinal Stromal Tumors (GISTs) Treatment Introduction
    • 11.3.4 Novartis Revenue in Gastrointestinal Stromal Tumors (GISTs) Treatment Business (2015-2020)
    • 11.3.5 Novartis Recent Development
  • 11.4 Immunicum
    • 11.4.1 Immunicum Company Details
    • 11.4.2 Immunicum Business Overview
    • 11.4.3 Immunicum Gastrointestinal Stromal Tumors (GISTs) Treatment Introduction
    • 11.4.4 Immunicum Revenue in Gastrointestinal Stromal Tumors (GISTs) Treatment Business (2015-2020)
    • 11.4.5 Immunicum Recent Development
  • 11.5 Roche
    • 11.5.1 Roche Company Details
    • 11.5.2 Roche Business Overview
    • 11.5.3 Roche Gastrointestinal Stromal Tumors (GISTs) Treatment Introduction
    • 11.5.4 Roche Revenue in Gastrointestinal Stromal Tumors (GISTs) Treatment Business (2015-2020)
    • 11.5.5 Roche Recent Development
  • 11.6 AB Science
    • 11.6.1 AB Science Company Details
    • 11.6.2 AB Science Business Overview
    • 11.6.3 AB Science Gastrointestinal Stromal Tumors (GISTs) Treatment Introduction
    • 11.6.4 AB Science Revenue in Gastrointestinal Stromal Tumors (GISTs) Treatment Business (2015-2020)
    • 11.6.5 AB Science Recent Development
  • 11.7 Arog Pharmaceuticals
    • 11.7.1 Arog Pharmaceuticals Company Details
    • 11.7.2 Arog Pharmaceuticals Business Overview
    • 11.7.3 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GISTs) Treatment Introduction
    • 11.7.4 Arog Pharmaceuticals Revenue in Gastrointestinal Stromal Tumors (GISTs) Treatment Business (2015-2020)
    • 11.7.5 Arog Pharmaceuticals Recent Development
  • 11.8 Boston Biomedical
    • 11.8.1 Boston Biomedical Company Details
    • 11.8.2 Boston Biomedical Business Overview
    • 11.8.3 Boston Biomedical Gastrointestinal Stromal Tumors (GISTs) Treatment Introduction
    • 11.8.4 Boston Biomedical Revenue in Gastrointestinal Stromal Tumors (GISTs) Treatment Business (2015-2020)
    • 11.8.5 Boston Biomedical Recent Development
  • 11.9 Sun Pharmaceutical
    • 11.9.1 Sun Pharmaceutical Company Details
    • 11.9.2 Sun Pharmaceutical Business Overview
    • 11.9.3 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GISTs) Treatment Introduction
    • 11.9.4 Sun Pharmaceutical Revenue in Gastrointestinal Stromal Tumors (GISTs) Treatment Business (2015-2020)
    • 11.9.5 Sun Pharmaceutical Recent Development
  • 11.10 Natco Pharma
    • 11.10.1 Natco Pharma Company Details
    • 11.10.2 Natco Pharma Business Overview
    • 11.10.3 Natco Pharma Gastrointestinal Stromal Tumors (GISTs) Treatment Introduction
    • 11.10.4 Natco Pharma Revenue in Gastrointestinal Stromal Tumors (GISTs) Treatment Business (2015-2020)
    • 11.10.5 Natco Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Gastrointestinal Stromal Tumors (GISTs) Treatment Scope and Market Size
    Gastrointestinal Stromal Tumors (GISTs) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Gastrointestinal Stromal Tumors (GISTs) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Surgery
    Targeted Therapy
    Radiation Therapy
    Chemotherapy
    Ablation
    Embolization
    Others

    Market segment by Application, split into
    Hospitals
    Clinics
    Ambulatory Surgical Centers
    Others

    Based on regional and country-level analysis, the Gastrointestinal Stromal Tumors (GISTs) Treatment market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Gastrointestinal Stromal Tumors (GISTs) Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Pfizer
    Bayer
    Novartis
    Immunicum
    Roche
    AB Science
    Arog Pharmaceuticals
    Boston Biomedical
    Sun Pharmaceutical
    Natco Pharma

    Buy now